These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 1334218)

  • 1. [The pharmacology of ganciclovir].
    Freie HM
    Med Klin (Munich); 1992 Oct; 87 Suppl 1():20-3. PubMed ID: 1334218
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU-183792, a 4-oxo-dihydroquinoline.
    Knechtel ML; Huang A; Vaillancourt VA; Brideau RJ
    J Med Virol; 2002 Oct; 68(2):234-6. PubMed ID: 12210413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir.
    Razonable RR; van Cruijsen H; Brown RA; Wilson JA; Harmsen WS; Wiesner RH; Smith TF; Paya CV
    J Infect Dis; 2003 Jun; 187(11):1801-8. PubMed ID: 12751039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of antiviral activity of different origin compounds by flow cytometry.
    Siennicka J; Trzcińska A; Kańtoch M
    Acta Microbiol Pol; 2002; 51(1):79-83. PubMed ID: 12184452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein.
    Michel D; Höhn S; Haller T; Jun D; Mertens T
    J Med Virol; 2001 Sep; 65(1):70-6. PubMed ID: 11505446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes.
    Bakker-Woudenberg IA; Lokerse AF; ten Kate M
    Scand J Infect Dis Suppl; 1990; 74():54-7. PubMed ID: 1965866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganciclovir-resistant human cytomegalovirus clinical isolates; resistance mechanisms and in vitro susceptibility to antiviral agents.
    Biron KK
    Transplant Proc; 1991 Jun; 23(3 Suppl 3):162-7. PubMed ID: 1648824
    [No Abstract]   [Full Text] [Related]  

  • 8. [In vitro susceptibility to ganciclovir and foscarnet of cytomegaloviruses].
    Otegui M; Rabella N; Labeaga R; Herrero M; Margall R; Muñoz JM; Prats G
    Rev Esp Quimioter; 2001 Jun; 14(2):155-64. PubMed ID: 11704769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir.
    Keever-Taylor CA; Behn B; Konings S; Orentas R; Davies B; Margolis D
    Cytotherapy; 2003; 5(4):323-35. PubMed ID: 12944239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ganciclovir and acyclovir on vascular cell proliferation of cytomegalovirus-positive and negative donors.
    Mohacsi PJ; Hulliger B; Wijngaard PL
    Transplant Proc; 1996 Dec; 28(6):3234-5. PubMed ID: 8962251
    [No Abstract]   [Full Text] [Related]  

  • 11. Interstitial pneumonitis during murine cytomegalovirus infection and graft-versus-host reaction: effect of ganciclovir therapy.
    Shanley JD; Pomeroy C; Via CS; Shearer GM
    J Infect Dis; 1988 Dec; 158(6):1391-4. PubMed ID: 2848905
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiviral activity of berberine and related compounds against human cytomegalovirus.
    Hayashi K; Minoda K; Nagaoka Y; Hayashi T; Uesato S
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1562-4. PubMed ID: 17239594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Action of acyclovir on cytomegalovirus in tissue culture and in chronic infection in women].
    Martynova VN; Farber NA; Demidova SA; Mironova LL; Preobrazhenskaia NK
    Vopr Virusol; 1988; 33(1):44-8. PubMed ID: 2835869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Strains of ganciclovir-resistant cytomegalovirus].
    Calicó I; García E; Cortés A; Gavaldá J; Roman A; Valle I
    Enferm Infecc Microbiol Clin; 1999; 17(7):330-4. PubMed ID: 10535184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
    West P; Schmiedeskamp M; Neeley H; Oberholzer J; Benedetti E; Kaplan B
    Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of three regimens for cytomegalovirus prophylaxis in 147 liver transplant recipients.
    Freise CE; Pons V; Lake J; Burke E; Ascher NL; Roberts JP
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1498-500. PubMed ID: 1846470
    [No Abstract]   [Full Text] [Related]  

  • 18. [Mechanisms of antiviral resistance among the herpesvirus group].
    Reina J
    Enferm Infecc Microbiol Clin; 1997; 15(6):329-34. PubMed ID: 9376408
    [No Abstract]   [Full Text] [Related]  

  • 19. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.
    Gilbert C; Roy J; Belanger R; Delage R; Beliveau C; Demers C; Boivin G
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3669-71. PubMed ID: 11709367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient.
    García-Martínez J; Folgueira L; Delgado R; Hernando S; Prieto C; Aguado JM; Otero JR
    Transpl Infect Dis; 2008 Apr; 10(2):123-8. PubMed ID: 17605746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.